stockrow
Saturday 7 November 2026
Export BRTX’s income statement to Excel — free account
Biorestorative Therapies, Inc.
BRTX Healthcare Biotechnology
Biorestorative Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $359,700.00, down 10.3% from fiscal 2024.
- Revenue
- −7.20%
- EPS
- +81.3%
- Free cash flow
- −35.3%
Quarter to March 2026, against a year earlier
1.48
0.03
−1.99%
Follow BRTX
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 5 | 2 | 2 | 3 | 4 | 4 | 4 | 3 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
37.36 | 18.27 | 64.86 | 0.92 | 141.23 | 112.09 | 82.14 | 49.76 | 27.69 | 29.38 |
Altman Z-Score |
(57.74) | (61.87) | (104.84) | (105.07) | (29.26) | (7.49) | (5.83) | (17.73) | (18.32) | (69.35) |
Altman Z″-Score (non-manufacturers) |
(144.45) | (157.35) | (268.71) | (275.34) | (68.64) | 5.29 | (4.59) | (37.43) | (41.31) | (162.40) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(1.28) | (1.09) | (4.64) | (0.07) | (19.00) | (4.50) | (6.09) | (4.57) | (4.73) | (4.38) |
Beneish M-Score |
(16.79) | (14.66) | (31.71) | (26.98) | (12.87) | (15.47) | (3.87) | (5.87) | 1.13 | (7.56) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.62 | 0.73 | 1.30 | 30.83 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.66 | 0.78 | 1.41 | 0.00 |
EV/Sales |
44.67 | 15.09 | 68.53 | 2.12 | 156.88 | (340.86) | (39.38) | (24.83) | 1.40 | 21.70 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.63 | 0.25 | 0.24 | 0.00 | 0.00 |
EV/Operating CF |
(0.32) | (0.32) | (1.49) | (0.04) | (6.15) | 4.71 | 0.80 | 0.56 | (0.07) | (0.72) |
EV/FCF |
(0.31) | (0.31) | (1.49) | (0.04) | (6.04) | 4.62 | 0.64 | 0.47 | (0.06) | (0.65) |
Quick Ratio |
0.01 | 0.06 | 0.02 | 0.00 | 2.95 | 57.81 | 33.53 | 4.25 | 2.91 | 0.80 |
Current Ratio |
0.01 | 0.06 | 0.02 | 0.01 | 3.05 | 59.01 | 34.36 | 4.37 | 2.97 | 0.84 |
Net Debt/EBITDA |
(0.04) | 0.03 | (0.08) | (0.11) | (0.89) | 0.83 | 0.78 | 0.74 | 0.94 | 0.19 |
Debt/Assets |
18.85% | 11.05% | 43.94% | 35.59% | 98.23% | 0.85% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.06) | (0.03) | (0.06) | (0.04) | (3.21) | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.05 | 0.08 | 0.10 | 0.03 | 0.00 | 0.01 | 0.01 | 0.03 | 0.04 |
Operating CF/Net income |
0.58 | 0.41 | 0.41 | 0.47 | 0.17 | 0.08 | 0.32 | 0.62 | 0.92 | 0.76 |
Capex/Depreciation |
(0.24) | 0.00 | (0.01) | (0.01) | 0.00 | (0.03) | (3.65) | (1.03) | (0.56) | (0.55) |
Interest Coverage |
(35.13) | (17.89) | (8.20) | (5.74) | (1.68) | (14.49) | 1,621.71 | 27.56 | 18.76 | 58.78 |
| 193.88% | 159.58% | 161.75% | 136.79% | 159.81% | (437.56%) | (98.91%) | (80.73%) | (97.03%) | (321.48%) | |
| (480.19%) | (565.79%) | (848.38%) | (1,101.88%) | (387.82%) | (330.62%) | (95.12%) | (71.73%) | (72.15%) | (174.11%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (2,159.78%) | (1,095.29%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
164.10% | 125.83% | 140.67% | 107.84% | (520.90%) | (209.55%) | (123.72%) | (113.99%) | (115.73%) | 6,268.49% |
Average Days of Receivables |
60.16 | 171.23 | 95.36 | 89.85 | 80.58 | 39.67 | 48.75 | 48.32 | 171.49 | 15.73 |
Research and Development Expense of Revenue |
7,921.98% | 2,657.28% | 1,363.24% | 1,324.85% | 1,138.70% | 1,585.00% | 2,932.72% | 2,767.22% | 1,672.54% | 2,806.42% |
Selling, General and Administrative Expense of Revenue |
13,565.38% | 7,781.36% | 5,626.58% | 5,261.31% | 2,535.32% | 55,706.09% | 13,005.43% | 7,772.29% | 1,302.04% | 1,637.00% |
Intangible Assets out of Total Assets |
0.61 | 0.51 | 0.68 | 0.50 | 0.15 | 0.03 | 0.05 | 0.06 | 0.05 | 0.13 |
Share Based Compensation of Revenue |
6,969.23% | 4,445.43% | 2,161.62% | 1,275.77% | 898.31% | 50,236.96% | 10,528.30% | 5,338.13% | 701.40% | 924.55% |
Graham Net Nets |
(4.78) | (5.46) | (1.34) | (118.11) | (0.23) | 4.00 | 1.48 | 1.21 | 0.67 | (0.06) |
Graham Number |
397,818.40 | 424,836.70 | 459,643.82 | 203,856.21 | 932.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(1,034.31%) | (792.79%) | (150.93%) | (10,842.47%) | (103.48%) | (887.71%) | (187.87%) | (146.86%) | (81.12%) | (135.32%) |
Free Cash Flow Yield |
(381.73%) | (267.32%) | (71.13%) | (5,795.25%) | (18.39%) | (65.87%) | (74.72%) | (107.18%) | (86.30%) | (114.31%) |
Revenue per Share |
709.28 | 1,195.04 | 1,163.77 | 466.84 | 3.90 | 0.77 | 0.66 | 0.69 | 1.03 | 0.80 |
Operating CF per Share |
(97,480.51) | (56,857.48) | (53,518.56) | (24,845.41) | (99.53) | (56.06) | (32.69) | (30.49) | (21.20) | (23.99) |
Capex per Share |
(3,678.88) | (53.11) | (135.25) | (127.84) | 0.00 | (0.52) | (2.43) | (0.81) | (0.27) | (0.26) |
Free Cash Flow per Share |
(101,159.39) | (56,910.59) | (53,653.81) | (24,973.25) | (99.53) | (56.58) | (35.12) | (31.30) | (21.47) | (24.25) |
Cash per Share |
619.64 | 6,664.21 | 1,231.91 | 6.10 | 155.29 | 353.98 | 81.53 | 52.47 | 27.65 | 6.57 |
Shareholders Equity per Share |
(97,433.75) | (100,864.56) | (90,595.51) | (45,879.99) | (67.47) | 363.59 | 87.52 | 47.44 | 21.98 | 0.79 |
Interest Debt per Share |
0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(97,433.75) | (100,864.56) | (90,595.51) | (45,879.99) | (67.47) | 363.59 | 87.52 | 47.44 | 21.98 | 0.79 |
Free Cash Flow |
(5.19) | (3.86) | (5.12) | (6.95) | (1.96) | (3.36) | (6.35) | (6.60) | (8.34) | (10.91) |
Working Capital |
(5.77) | (7.83) | (9.07) | (13.65) | 2.14 | 21.10 | 14.69 | 8.78 | 7.40 | (0.59) |
Capital Expenditures |
(0.19) | 0.00 | (0.01) | (0.04) | — | (0.03) | (0.44) | (0.17) | (0.11) | (0.12) |
Net Current Asset Value |
(6.51) | (8.08) | (9.65) | (14.17) | (2.49) | 20.61 | 14.53 | 8.78 | 7.40 | (0.59) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.60 | 0.25 | 0.24 | 0.00 | 0.00 |
Capex to Sales |
5.19 | 0.04 | 0.12 | 0.27 | 0.00 | 0.67 | 3.67 | 1.17 | 0.26 | 0.32 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.57 | 2.68 | 14.44 | 56.85 | 63.90 | 32.17 | 0.46 | 0.47 | 0.52 | 0.59 |
Cash ROIC |
111.15% | 62.31% | 63.97% | 56.76% | (32.72%) | (7.85%) | (20.77%) | (31.33%) | (43.28%) | (329.50%) |
Accounts Receivable Turnover |
0.73 | 3.68 | 3.31 | 4.26 | 3.14 | 4.18 | 11.41 | 8.26 | 3.86 | 3.53 |
Accounts Payable Turnover |
0.00 | 0.11 | 0.00 | 0.00 | 0.00 | 2.42 | 2.53 | 0.00 | 0.08 | 0.03 |
Inventory Turnover |
0.00 | 0.00 | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
Average Days of Payables |
8,336,600.00 | 3,455.61 | 0.00 | 0.00 | 0.00 | 90.36 | 222.22 | 0.00 | 6,275.14 | 20,573.42 |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
Average Receivables |
0.05 | 0.02 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.02 | 0.10 | 0.10 |
Average Payables |
2.42 | 2.37 | 2.17 | 1.92 | 1.04 | 0.08 | 0.11 | 0.18 | 0.34 | 0.91 |
Average Assets |
1.80 | 1.67 | 1.48 | 1.33 | 2.91 | 13.40 | 19.44 | 14.52 | 12.45 | 8.18 |
Average Common Equity |
(4.45) | (5.92) | (7.74) | (10.71) | (7.05) | 10.13 | 18.70 | 12.90 | 9.25 | 4.43 |
Columns are period end dates · fundamentals updated 26 Oct 2026